On August 13, 2022 UnogenBio reported the company has completed the angel financing of RMB 50 million in early January 2022. Invested exclusively by Lapam Capital headquartered in Beijing, the financing aims to support the technology layout of UnogenBio in multiple fields of innovative cancer treatment (Press release, Unogen Biotech, AUG 13, 2022, View Source [SID1234643978]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Established in 2021, UnogenBio is committed to developing anti-tumor drugs of world-class technology in order to satisfy unmet treatment needs. The entrepreneurial team of UnogenBio has full-chain and all-round success experiences from drug research and development to clinic. Ms. Fiona Yu, graduated from MIT, is the CEO of UnogenBio. With years of experience in business management and deep research in the development strategy of biotechnology, her book, The Success Code of Pharmaceutical Giants, is highly praised in the industry. With a passion for biotechnology, Fiona has co-founded UnogenBio with several senior scientific partners. Both CSO and CMO of the company served as executives at multinational pharmaceutical companies or the FDA. They have worked in the pharmaceutical industry for decades, and made innumerable achievements. At the present stage, the core assets of UnogenBio include two small molecule drugs of CD3 redirected multi antibodies (in study) and two small molecule drugs that turn cold tumors into hot tumors. Besides, the company is building a wholly new R&D platform and expanding its business lines actively. It will lay emphasis on the gamma-delta T cells and some innovative targets and technologies that are not available for producing drugs.
Lapam Capital is a leading venture capital institution in biological medicine industry in China. Lapam Capital, with a total size greater than RMB 6 billion, has four RMB funds and one dollar fund under its management, and owns the only special fund for biological medicine funded by the Social Security Fund of the People’s Republic of China so far. Focusing on investing in quality projects in the segments of innovative drugs and medical devices, Lapam Capital mainly invests in projects at the start-up, early and middle stages. By now, Lapam Capital has invested in over 50 innovative drug companies and over 10 innovative medical device companies, incubated and supported a large number of well-known pharmaceutical companies, including Betta Pharmaceuticals, RemeGen, Clover Biopharmaceuticals, Asieris Pharmaceuticals, Stemirna Therapeutics, Binhui Biopharm, ImmuneOnco, Biostar, Eyebright, and other star enterprises Multiple partners of Lapam Capital have over two decades of experience in research, development and management of international/domestic biological medicine industry, and are qualified for providing comprehensive value-added services to the invested enterprises.
According to Ms. Fiona Yu, it is UnogenBio’s great honor to receive trust and support from Lapam Capital. The excellent investment performance of Lapam Capital would be the best endorsement for a technology company at the start-up. Lapam Capital is not just our financial investor, and the industry resources and human relations it provides will make our future development easier and faster. For now, the company has completed its arrangements in USA, and is planning its domestic research and development platform actively and vigorously. Domestic scientists with a passion for innovative technology are welcome to join us to work together for the future of innovative medicine in China. –
Mr. Yu Zhihua, Chairman of Lapam Capital, believes that UnogenBio is a unique company. Although it is a newly-established company, it has a relatively whole team of senior experts in drug discovery, preclinical and clinical stages, considering R&D and operation. The company’s projects have fully considered product differentiation and advanced technologies, and have abilities in technical innovation and external resource integration. UnogenBio shows its own particular potential in team comprehensiveness and balance, as well as in foundation and direction of scientific researches. So we are optimistic about the future of UnogenBio.